BC
SPRY icon

Bridgefront Capital’s ARS Pharmaceuticals SPRY Stock Holding History

Bridgefront Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12,926
Closed -$104K – 738
2026
Q1 		$104K Buy
+12,926
New +$124K 0.03% 496

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Bridgefront Capital's SPRY Position: Q2 2026 in Review

Bridgefront Capital sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 12,926 shares — an estimated $104K sold.

Bridgefront Capital first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $104K in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Bridgefront Capital reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 12,926 ARS Pharmaceuticals shares in Q2 2026, an estimated $104K.
  • Bridgefront Capital first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Bridgefront Capital's ARS Pharmaceuticals position peaked at $104K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.